Recon: Pfizer seeks clearance for COVID vaccine boosters; Court revives 6,000 suits over 3M surgical warming device

• Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster (WSJ) (Reuters)
• US expected to recommend Covid-19 vaccine booster shots for all (AP) (Reuters)
• Antibody Cocktails to Treat Covid Take Off as Delta Surges (Bloomberg)
• U.S. court revives nearly 6,000 lawsuits over 3M surgical warming device (Reuters) (Law360)
• Dueling 7-figure ad campaigns set sights on a big drug price negotiation bill coming soon (Endpoints)
• Eli Lilly unveils a complete makeover, erecting a neuroscience unit centered on Alzheimer's as it unifies oncology biz (Endpoints) (Fierce)
• Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle (Endpoints)

• Cote d'Ivoire starts Ebola vaccination of frontline workers (WHO)
• UK regulator approves Moderna COVID-19 shot for 12 to 17-year-olds (Reuters)
• Roche warns of global Actemra shortage as Delta variant drives huge spike in demand for COVID-19 patients (Fierce) (Endpoints) (Roche)
• Higher risk of Bell's Palsy after Sinovac's COVID-19 vaccine – study (Reuters)

• Thermo Fisher's COVID tests snare FDA green light for detecting delta and other variants (Fierce)
• ‘Tainted’ Blood: Covid Skeptics Request Blood Transfusions From Unvaccinated Donors (KHN)
• Novavax taps Sanofi, Supernus vets amid quest to get its COVID-19 vaccine over the FDA finish line (Fierce)

• Discovery of rare mutation in a brain protein adds fuel to debate over cause of Alzheimer’s disease (STAT)
• This Breast Cancer Gene Is Less Well Known, but Nearly as Dangerous (NYTimes)
• It’s PANDA-monium at FDA (FDA Law Blog)
• Scoop: Adam Koppel's Bain team has another $1.9B to wager on life sci companies. And he likes their odds (Endpoints) (BioPharmaDive)
• Biosimilars versus biologics: Is marketing madness on the way as biosimilar approvals balloon? (Fierce)
• AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis (Pink Sheet)
• Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive (Pink Sheet)
• Magic mushrooms and 'toad venom' get this British biotech an oversubscribed Series B (Endpoints)
• InnoCare bags Chinese rights to Incyte CAR-T rival Monjuvi in bid to expand in-house pipeline (Endpoints)

• CMS To Discuss ’Gaps In Evidence‘ In Device Trials For Certain Cerebral Conditions (MedtechInsight)
• Abbott's Amulet FDA approval sets stage for US market fight with Boston Scientific (MedtechDive)
• ResMed unveils new sleep apnea machine amid scramble to fill void left by Philips' CPAP recall (Fierce)

• 5 years after Pfizer buyout, SEC charges Medivation's ex-dealmaking lead with insider trading (Fierce)
• Sackler Reps Say They Can't Sell Assets Without Releases (Law360)
• Judge Lets Dana-Farber Advance Cancer Drug IP Suit (Law360)
• Biotech Says Celgene-BMS Deal Threatens Drug Development (Law360)
• Witness's COVID-19 Diagnosis Delays CR Bard Implant Trial (Law360)